Suppr超能文献

在癌症恶病质大鼠模型中,胃饥饿素治疗可导致食物摄入量增加以及瘦体重保持。

Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia.

作者信息

DeBoer Mark D, Zhu Xin Xia, Levasseur Peter, Meguid Michael M, Suzuki Susumu, Inui Akio, Taylor John E, Halem Heather A, Dong Jesse Z, Datta Rakesh, Culler Michael D, Marks Daniel L

机构信息

Center for the Study of Weight Regulation, Oregon Health and Science University, 707 SW Gaines Road, Portland, OR 97239, USA.

出版信息

Endocrinology. 2007 Jun;148(6):3004-12. doi: 10.1210/en.2007-0016. Epub 2007 Mar 8.

Abstract

Cancer cachexia is a debilitating syndrome of anorexia and loss of lean body mass that accompanies many malignancies. Ghrelin is an orexigenic hormone with a short half-life that has been shown to improve food intake and weight gain in human and animal subjects with cancer cachexia. We used a rat model of cancer cachexia and administered human ghrelin and a synthetic ghrelin analog BIM-28131 via continuous infusion using sc osmotic minipumps. Tumor-implanted rats receiving human ghrelin or BIM-28131 exhibited a significant increase in food consumption and weight gain vs. saline-treated animals. We used dual-energy x-ray absorptiometry scans to show that the increased weight was due to maintenance of lean mass vs. a loss of lean mass in saline-treated animals. Also, BIM-28131 significantly limited the loss of fat mass normally observed in tumor-implanted rats. We further performed real-time PCR analysis of the hypothalami and brainstems and found that ghrelin-treated animals exhibited a significant increase in expression of orexigenic peptides agouti-related peptide and neuropeptide Y in the hypothalamus and a significant decrease in the expression of IL-1 receptor-I transcript in the hypothalamus and brainstem. We conclude that ghrelin and a synthetic ghrelin receptor agonist improve weight gain and lean body mass retention via effects involving orexigenic neuropeptides and antiinflammatory changes.

摘要

癌症恶病质是一种伴随多种恶性肿瘤出现的、导致厌食和瘦体重减轻的衰弱综合征。胃饥饿素是一种半衰期较短的促食欲激素,已证明它能改善患有癌症恶病质的人类和动物的食物摄入量和体重增加。我们使用癌症恶病质大鼠模型,通过皮下渗透微型泵持续输注给予人胃饥饿素和一种合成胃饥饿素类似物BIM-28131。与接受生理盐水治疗的动物相比,接受人胃饥饿素或BIM-28131的肿瘤植入大鼠的食物消耗量和体重增加显著增加。我们使用双能X线吸收测定扫描来表明体重增加是由于瘦体重的维持,而生理盐水治疗的动物瘦体重减少。此外,BIM-28131显著限制了肿瘤植入大鼠中通常观察到的脂肪量损失。我们进一步对下丘脑和脑干进行实时PCR分析,发现胃饥饿素治疗的动物下丘脑促食欲肽刺鼠相关肽和神经肽Y的表达显著增加,而下丘脑和脑干中IL-1受体-I转录本的表达显著降低。我们得出结论,胃饥饿素和一种合成胃饥饿素受体激动剂通过涉及促食欲神经肽和抗炎变化的作用改善体重增加和瘦体重保留。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验